Peptide Science
Peptide Science

Retour aux peptides

Thymosin Beta-4

Full-length 43-amino-acid protein, the natural parent of TB-500. Unlike the fragment, the full-length variant has a formal clinical track record (RegeneRx programme: dry-eye drops, venous-ulcer topical gel). Routinely confused with TB-500 in the grey market.

Research chemicalWADA S2 prohibitedInjectableTopical / ophthalmicRepair
Key facts
Common routesSC, topical, ophthalmic
Half-lifeShort (minutes to hours)
Typical range300–500 mcg/day
Résumé

Thymosin Beta-4 (TÎČ4) is the naturally occurring full-length 43-amino-acid protein produced by the thymus and present in most mammalian tissues. Its fundamental job is actin sequestration - it binds G-actin monomers, regulating the cytoskeletal pool cells need to migrate, differentiate, and repair.

TÎČ4 is the parent molecule of TB-500. TB-500, in turn, is the synthetic 7-amino-acid fragment LKKTETQ - the active domain, isolated. Most grey-market vials labelled “Thymosin Beta-4” are actually TB-500. The distinction matters: TÎČ4 has a formal clinical trial programme (RegeneRx), TB-500 doesn't. Users who explicitly want the full-length protein need to ask vendors directly.

Not the same as TB-500
TB-500 is the 7-amino-acid fragment (LKKTETQ) of the active domain. TÎČ4 is the full 43-amino-acid protein. Mechanism overlaps heavily, but the clinical track record belongs to TÎČ4: RGN-259 (eye drops, completed Phase 2/3 trials for dry eye), RGN-137 (topical gel for venous stasis ulcers), RGN-352 (injectable). Most grey-market “TÎČ4” vials are actually TB-500.
Notes sur le mécanisme
Actin sequestration
Binds G-actin monomers and prevents their polymerisation into F-actin filaments until needed. Maintains an instantly-available pool of building blocks for rapid cytoskeletal remodelling - the substrate for cell migration. Repair cells (keratinocytes, endothelial cells) reach injury sites through this mechanism.
Angiogenesis and wound healing
Promotes endothelial cell migration and differentiation. Tube formation in vitro is robustly documented. Clinically, this is what drives the topical and ophthalmic programmes - bringing new blood vessels to damaged tissue, plus the migration component.
Anti-inflammatory and anti-fibrotic
Downregulates TNF-α and other inflammatory cytokines. Reduces fibroblast-to-myofibroblast differentiation - useful in healing because it constrains scar formation. Plus an anti-apoptotic component in ischemic tissue.
Dosing patterns
Systemic repair (injectable)
300–500 mcg SC daily for 14–28 day cycles. Daily frequency reflects short systemic half-life; weekly total (~2–3.5 mg) lands in the same range as typical TB-500 protocols, but the daily pattern is different. Users who port TB-500 weekly-bolus schemes onto TÎČ4 are running it wrong.
Topical / ophthalmic
Clinically developed as 0.02–0.1% concentration in gel or eye-drop formulations, applied 1–4 times daily. Injectable vials aren't formulated for eye or skin use unless specifically prepared. Home-mixed creams from reconstituted powder aren't what was used in the clinical trials.
Cycle discipline
Like BPC-157 / TB-500, TÎČ4 is angiogenic - the cancer-risk caution from the growth-factor frame applies. Standard practice: 4–6 weeks on, equal washout minimum. Don't run year-round. Active cancer history is a hard contraindication.
Aperçu des données
Tier: Clinical for topical / ophthalmic indications (Phase 2/3 trials completed); Preclinical for systemic athletic repair. Rating B+ - one of the more formal trial histories in the repair-peptide space, but the trials targeted specific eye and skin indications, not tendon repair or general recovery.
Human data
RGN-259 (eye drops) showed improvements in dry-eye symptoms and surface staining in Phase 2/3 trials. RGN-137 (topical gel) showed wound-healing acceleration in a subgroup of patients with smaller venous ulcers; mixed results on larger wounds. Systemic athletic-repair outcomes are extrapolated, not directly demonstrated.
Animal and mechanistic data
Robust preclinical data in cardiac ischaemia models - reduced injury size, improved functional recovery, suggestions of cardiomyocyte protection. In-vitro endothelial cell migration and tube-formation data consistent across labs. The mechanistic story is clear; translation to human tendon repair remains open.
Considérations de sécurité
Well-tolerated in the trial readouts. Practically, the main risks are product-identity confusion (TB-500 sold as TÎČ4), cancer caution because of angiogenesis, and longer systemic exposure - as a full-length protein TÎČ4 carries higher theoretical immunogenicity risk than the 7-amino-acid fragment, even though it's endogenous.
Common cautions
  • Product identity: most grey-market “TÎČ4” vials are actually TB-500 - ask vendors explicitly for full-length protein and confirm with HPLC
  • Active cancer is a hard contraindication; cancer history is a risk-aware caution (angiogenesis mechanism)
  • Injectable vials aren't formulated for topical or ophthalmic use - the clinical trials used purpose-built formulations
  • Don't run year-round - angiogenic load accumulates without proportional repair benefit outside an injury window